FindTrial
Sign In

Clinical study of TA-650 in patients with ankylosing spondylitis

Clinical study of TA-650 in patients with ankylosing spondylitis

Status
Unknown
Phases
Phase 3
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT2080220341
Enrollment
Unknown
Registered
2007-01-22
Start date
2007-01-22
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ankylosing spondylitis

Interventions

investigational material(s) Generic name etc : TA-650 (Infliximab) INN of investigational material : Therapeutic category code : 239 Other agents affecting digestive organs Dosage and Administration

Sponsors

Tanabe Pharma Corporation
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: [Inclusion criteria] Patients of 16 years and above who have had a diagnosis of definite ankylosing spondylitis, receiving a stable dose of Nonsteroidal anti inflammatory drugs (NSAIDs) or intolerant to NSAIDs, and who have disease activity. [Exclusion criteria] Patients who have previously used any anti-TNFalpha therapy, have a history of serious infection which caused hospitalization within 6 months before the registration, have an active tuberculosis, have a complication or a history of malignancy within 5 years before the registration.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Efficacy (clinical response), Safety and Pharmacokinetics—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026